ArticleInflammation2026
IRF7 Modulates Inflammatory Pain Through Upregulating IFNβ in Mice Trigeminal Ganglion.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite the high global burden of chronic pain, current therapeutic options remain limited. The transcription factor IRF7, primarily known for its role in immunity, has emerged as a potential regulator of nociception. However, a significant knowledge gap exists regarding its peripheral functions and mechanisms in orofacial pain. This study investigates the hypothesis that IRF7 and its downstream effector IFNβ act within the trigeminal ganglion (TG) to modulate orofacial pain pathways. The expression levels of IRF7 and IFNβ in the TG were evaluated in a mouse model of orofacial inflammatory pain. IRF7 was knocked down in the TG using AAV-mediated shRNA delivery. The functional interaction between IRF7 and IFNβ was tested through applying exogenous IFNβ, blocking its receptor, and performing a key rescue experiment to test if IFNβ reconstitution could reverse the effects of IRF7 loss. Inflammatory pain led to a significant upregulation of IRF7 and IFNβ in the TG neuron. IRF7 knockdown alleviated mechanical allodynia, reduced spinal neuronal activation, and suppressed pro-inflammatory mediators (IL-6 and NLRP3). Exogenous IFNβ exacerbated pain hypersensitivity and the nociceptive effects was attenuated by IFNAR antagonism. IFNβ rescued the pain modulation deficits resulting from IRF7 knockdown. Supplementing exogenous IFNβ rescued the pain modulation deficits resulting from IRF7 knockdown in an inflammatory pain condition. Our findings demonstrate that the peripheral IRF7–IFNβ axis drives inflammatory pain pathogenesis, identifying a novel therapeutic target for chronic pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.